BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 22193779)

  • 21. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
    Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
    Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
    Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
    Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.
    Luszczak S; Simpson BS; Stopka-Farooqui U; Sathyadevan VK; Echeverria LMC; Kumar C; Costa H; Haider A; Freeman A; Jameson C; Ratynska M; Ben-Salha I; Sridhar A; Shaw G; Kelly JD; Pye H; Gately KA; Whitaker HC; Heavey S
    Sci Rep; 2020 Sep; 10(1):14380. PubMed ID: 32873828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
    Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6.
    Menezes SV; Kovacevic Z; Richardson DR
    J Biol Chem; 2019 Mar; 294(11):4045-4064. PubMed ID: 30679310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth.
    Singh N; Padi SKR; Bearss JJ; Pandey R; Okumura K; Beltran H; Song JH; Kraft AS; Olive V
    Mol Oncol; 2020 May; 14(5):974-990. PubMed ID: 32146726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells.
    Yoon YK; Kim HP; Song SH; Han SW; Oh DY; Im SA; Bang YJ; Kim TY
    Cancer Lett; 2012 Mar; 316(1):77-84. PubMed ID: 22082529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma.
    Cervantes-Gomez F; Chen LS; Orlowski RZ; Gandhi V
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S317-29. PubMed ID: 23988451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SGI-1776, an imidazo pyridazine compound, inhibits the proliferation of ovarian cancer cells by inactivating Pim-1.
    Xie J; Bai J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 39(7):649-57. PubMed ID: 25080901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells.
    Sen A; O'Malley K; Wang Z; Raj GV; Defranco DB; Hammes SR
    J Biol Chem; 2010 Sep; 285(37):28787-95. PubMed ID: 20628053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6.
    Wendt MK; Williams WK; Pascuzzi PE; Balanis NG; Schiemann BJ; Carlin CR; Schiemann WP
    Neoplasia; 2015 Jan; 17(1):124-33. PubMed ID: 25622905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.
    Hoeben A; Martin D; Clement PM; Cools J; Gutkind JS
    Int J Cancer; 2013 Mar; 132(5):1042-50. PubMed ID: 22865653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
    Cragg MS; Kuroda J; Puthalakath H; Huang DC; Strasser A
    PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Negative regulation of the EGFR-MAPK cascade by actin-MAL-mediated Mig6/Errfi-1 induction.
    Descot A; Hoffmann R; Shaposhnikov D; Reschke M; Ullrich A; Posern G
    Mol Cell; 2009 Aug; 35(3):291-304. PubMed ID: 19683494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene 33 is an endogenous inhibitor of epidermal growth factor (EGF) receptor signaling and mediates dexamethasone-induced suppression of EGF function.
    Xu D; Makkinje A; Kyriakis JM
    J Biol Chem; 2005 Jan; 280(4):2924-33. PubMed ID: 15556944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells.
    Sun Q; Ming L; Thomas SM; Wang Y; Chen ZG; Ferris RL; Grandis JR; Zhang L; Yu J
    Oncogene; 2009 Jun; 28(24):2348-57. PubMed ID: 19421143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutation of epidermal growth factor receptor is associated with MIG6 expression.
    Nagashima T; Ushikoshi-Nakayama R; Suenaga A; Ide K; Yumoto N; Naruo Y; Takahashi K; Saeki Y; Taiji M; Tanaka H; Tsai SF; Hatakeyama M
    FEBS J; 2009 Sep; 276(18):5239-51. PubMed ID: 19674104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells.
    Ohta T; Ohmichi M; Shibuya T; Takahashi T; Tsutsumi S; Takahashi K; Kurachi H
    Cancer Biol Ther; 2012 Apr; 13(6):408-16. PubMed ID: 22313686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential parsing of EGFR endocytic flux among parallel internalization pathways in lung cancer cells with EGFR-activating mutations.
    Walsh AM; Lazzara MJ
    Integr Biol (Camb); 2014 Mar; 6(3):312-23. PubMed ID: 24445374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.